Viking Therapeutics Reports Positive VK2735 Weight Results
San Diego, California, U.S., September 22, 2026 Viking Therapeutics, Inc. has announced positive topline results from a maintenance study...
GIP
Advertisement
Zealand Pharma Initiates Phase 3 ZUPREME Program for Petrelintide
COPENHAGEN, Denmark — September 22, 2026 Zealand Pharma announced the initiation of the global registrational Phase 3a ZUPREME program...
Syntis Bio Advances Oral SYNT-101 Toward Phase 2
BOSTON — September 15, 2026 Syntis Bio, Inc. announced results from the 28-day multiple-ascending-dose (MAD) portion of its Phase...
Ascletis Joins Hong Kong Stock Connect Programs
Hong Kong, September 7, 2026 Ascletis Pharma Inc. has announced that its ordinary shares have been included as eligible...
Eli Lilly Links Zepbound to Lower Healthcare Costs
Zepbound Use Associated With Lower Healthcare Costs INDIANAPOLIS, Aug. 26, 2026 — Eli Lilly and Company announced new real-world...
Advertisements
Ascletis Launches Global Phase III Trial of Oral GLP-1 ASC30
Hong Kong – August 3, 2026 Ascletis Pharma Inc. has initiated a global Phase III clinical development program for...
Eli Lilly Reports Positive Phase 3 Retatrutide Results
INDIANAPOLIS, July 23, 2026 Eli Lilly and Company has announced positive topline results from the Phase 3 TRIUMPH-2 and...
Boehringer Ingelheim Advances BI 3034701 into Phase II Obesity Trial
INGELHEIM, Germany, July 16, 2026 Boehringer Ingelheim has initiated a Phase II clinical trial evaluating BI 3034701, an investigational...
Viking Therapeutics Launches Phase 1 Study of VK3019 for Weight Loss
SAN DIEGO, June 24, 2026 Viking Therapeutics (NASDAQ: VKTX) announced the initiation of a Phase 1 clinical trial evaluating...
LIR Shows Successful Needle-Free Delivery of GLP-1 Therapies
VANCOUVER, Canada, June 17, 2026 LIR Life Sciences Corp. announced the successful completion of its comparative preclinical animal study...
Advertisement
